Capital Fund Management S.A. Bluebird Bio, Inc. Put Options Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2019 Aug 12, 2019	SELL	$75.84 - $105.21 $128,928 - $178,857	-1,700 Reduced 28.81%	4,200 $534,000
Q1 2019 May 13, 2019	BUY	$64.44 - $104.11 $161,100 - $260,275	2,500 Added 73.53%	5,900 $928,000
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $112,290 - $177,194	-1,900 Reduced 35.85%	3,400 $337,000
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $257,694 - $340,721	2,900 Added 120.83%	5,300 $774,000
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $1.03 Million - $1.31 Million	-10,300 Reduced 81.1%	2,400 $377,000
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $317,400 - $452,820	3,000 Added 30.93%	12,700 $2.17 Million
Q4 2017 Feb 09, 2018	BUY	$81.25 - $130.7 $788,125 - $1.27 Million	9,700	9,700 $1.73 Million

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $765M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.